Based on the results of numerous preclinical, epidemiological and clinical studies outside the FA setting, metformin can also suppress carcinogenesis by lowering insulin levels and inhibiting the mammalian target of rapamycin (mTOR) pathway, both of which play key roles in cancer metabolism and proliferation [181,182]. Here, MTOR is linked to cancer.